Tobin, Evan <br/><br/>
Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines.  [electronic resource] 

 -  Leukemia & lymphoma  May 2007 
 - 944-56 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1042-8194 
<br/><br/><label>Standard No.: </label>10.1080/10428190701272272  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--chemistry<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD20--biosynthesis<br/>Antineoplastic Agents--therapeutic use<br/>Caspase 3--metabolism<br/>Cell Line, Tumor<br/>Cell Survival<br/>Complement System Proteins<br/>Drug Screening Assays, Antitumor<br/>Enzyme Activation<br/>HLA-DR Antigens--therapeutic use<br/>Humans<br/>Immunotherapy--methods<br/>Lymphoma--immunology<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Rituximab